Liraglutide (CAS No.: 204656-20-}2) - Long-Acting GLP-1 Receptor Agonist for Type 2 Diabetes & Obesity Management
Raws li tus kws tshaj lij kev lag luam ntawm cov kws kho mob - qib peptide cov khoom xyaw tshuaj nquag (APIs), peb muab siab -Liraglutide purity uas nruj me ntsis ua raws li cov qauv tshuaj thoob ntiaj teb (USP, EP, BP). Ib qho recombinant glucagon-zoo li peptide-1 (GLP-1) receptor agonist, nws ua raws li qhov kev txiav txim ntawm endogenous GLP-1 los tswj cov ntshav qabzib thiab txo lub cev hnyav-ua rau nws ua tus neeg sawv cev tseem ceeb rau hom 2 mob ntshav qab zib mellitus (T2DM) thiab kev tswj kev rog ntev rau cov neeg laus.
Product Basic Information
| Yam khoom | Paub meej |
|---|---|
| Khoom npe | Liraglutide |
| CAS Nr. | 204656-20-2 |
| Molecular Formula | C₁₇₄H₂₆₆N₄₄O₅₁ |
| Molecular Luj | 3751.25 |
| Qhov tshwm sim | Dawb rau tawm -dawb amorphous hmoov; Tsis hnov tsw |
| Specification | Pharmaceutical qib; Purity Ntau dua lossis sib npaug li 99.0% (HPLC); Poob ntawm ziab Tsawg dua lossis sib npaug li 3.0%; Residue ntawm ignition Tsawg dua los yog sib npaug rau 0.1%; Cov hlau hnyav (Pb, Hg, Cd) Tsawg dua lossis sib npaug li 10ppm; Cov kuab tshuaj residue (acetonitrile, trifluoroacetic acid) ua raws li ICH Q3C txwv; Endotoxin Tsawg dua lossis sib npaug rau 0.25 EU / mg |
Product Core Functions & Applications
Liraglutide CAS # 204656-20-2 exerts nws cov tshuaj pharmacological los ntawmxaiv qhib GLP-1 receptors(tshwj xeeb hauv cov txiav, lub hlwb, thiab plab hnyuv), uas hais txog cov txheej txheem pathophysiological tseem ceeb ntawm T2DM thiab rog. Nws qhov txiaj ntsig tseem ceeb yog a24-teev ib nrab-lub neej, ua kom ib zaug -kev tswj hwm subcutaneous txhua hnub thiab cov ntshav siab ruaj khov- txhim kho kev ua raws li tus neeg mob zoo. Nws tsuas yog siv rau hauv tib neeg cov tshuaj formulations:
1. Kev kho mob ntshav qab zib hom 2 (T2DM).
Monotherapy: Rau cov neeg mob T2DM uas tsis tuaj yeem zam cov metformin lossis muaj kev txwv tsis pub ua ntej - cov kab mob hauv qhov ncauj, nws txo qis ntshav qabzib / postprandial ntshav thiab txo qis glycated hemoglobin (HbA1c) los ntawm 1.0-1.5%.
Kev Kho Mob Ua Ke: Siv nrog metformin, sulfonylureas, SGLT2 inhibitors, lossis insulin txhawm rau txhim kho glycemic tswj-thaum offsetting qhov hnyav nce los ntawm insulin / sulfonylureas (qhov hnyav nruab nrab ntawm 1-3kg hauv kev siv ua ke).
Kev tiv thaiv kab mob plawv: Txo qhov kev pheej hmoo ntawm cov teeb meem loj ntawm cov hlab plawv (MACE, xws li, myocardial infarction, stroke) hauv T2DM cov neeg mob uas muaj kab mob plawv lossis mob plawv siab.
2. Kev Tswj Kev Noj Qab Haus Huv Ntev
Qhia rau cov neeg laus uas muaj qhov hnyav ntawm lub cev (BMI) Ntau dua lossis sib npaug li 30 kg / m² (obesity) lossis BMI Ntau dua lossis sib npaug li 27 kg / m² (hnyav) nrog tsawg kawg ib qhov hnyav -txog comorbidity (xws li, kub siab, dyslipidemia, T2DM).
Ua kom muaj kev poob phaus (nruab nrab 5-7% ntawm qhov hnyav tshaj 52 lub lis piam) los ntawm kev ua kom qab los noj mov (los ntawm kev tswj hwm lub paj hlwb hauv nruab nrab) thiab ua rau lub plab zom mov qeeb-txo cov zaub mov tsis muaj kev tshaib plab hnyav.
Daim ntawv noj tshuaj
Cov tshuaj txhaj tshuaj: Ua ntej- cov cwj mem puv (6 mg / mL, 12 mg / mL) rau kev txhaj tshuaj subcutaneous (lub plab, ncej puab, sab caj npab), muab tshuaj ib zaug ib hnub. Cov koob tshuaj maj mam nce ntxiv (pib los ntawm 0.6 mg / hnub) kom txo qis kev mob plab hnyuv.
Quality & Safety Assurance
raws li qhov siab -potency peptide API, yuav tsum muaj kev tswj xyuas nruj kom ntseeg tau tias kev ua tau zoo, ruaj khov, thiab kev nyab xeeb hauv chaw kho mob:
Raw Material Sourcing & Production
Precursor Control: Siv recombinant E. coli-qhia GLP-1 analog precursors thiab siab-purity hluavtaws fatty acid chains (kom ntev ib nrab neej ntawm albumin khi), zam impurities uas yuav cuam tshuam rau receptor affinity los yog ua rau lub cev tiv thaiv kab mob.
Kev tsim khoom: Ua nyob rau hauv GMP- ntawv pov thawj cleanrooms los ntawm cov khoom-theem peptide synthesis (SPPS), tom qab los ntawm post-kev hloov pauv kev hloov pauv (fatty acid conjugation) thiab ntau- kauj ruam purification (siab-kev ua haujlwm kua chromatography, HPLC). Kev tswj nruj nruj ntawm kev sib txuas ua haujlwm tau zoo thiab cov kauj ruam tiv thaiv kom ntseeg tau batch-rau-batch sib xws.
Comprehensive Testing Protocols
Txhua batch raug kuaj nruj kom ua tau raws li cov qauv tshuaj pharmacopoeia thoob ntiaj teb:
Purity & Lwm yam khoom: HPLC tsom xam (purity Ntau dua lossis sib npaug li 99.0%, ib qho impurity Tsawg dua lossis sib npaug li 0.5%, tag nrho impurities Tsawg dua lossis sib npaug li 1.0%).
Peptide Identity: Pom zoo los ntawm huab hwm coj spectrometry thiab amino acid sequence tsom xam.
Kev kuaj lub cev & tshuaj: Kev hloov kho qhov muag tshwj xeeb (+63℃rau +73℃, hauv 0.1M acetic acid), cov dej noo (Karl Fischer txoj kev Tsawg dua lossis sib npaug li 3.0%), thiab pH (6.0-8.0 rau aqueous tov).
Kev ntsuam xyuas kev nyab xeeb: Kev kuaj xyuas cov hlau hnyav (ICP-MS), kuaj kab mob microbial (tag nrho cov aerobic microbial suav Tsawg dua lossis sib npaug li 100 CFU/g), kuaj tsis muaj menyuam (rau txhaj tshuaj - qib API), thiab kuaj endotoxin (tsawg dua lossis sib npaug rau 0.25 EU/mg).
Kev ceeb toom kev nyab xeeb
Cov teebmeem tshwm sim: Cov tshuaj tiv thaiv kab mob plab (xws li, raws plab, cem quav, ntuav)-feem ntau me me mus rau nruab nrab, tshwm sim hauv thawj koob tshuaj - theem nce thiab txhim kho nrog kev siv txuas ntxiv.
Kev pheej hmoo loj:
Pancreatitis: Saib xyuas qhov mob plab hnyav heev (nrog xeev siab / ntuav); txiav tawm tam sim yog tias xav tias.
Thyroid C-Cell Tumor Risk: Contraindicated nyob rau hauv cov neeg mob uas muaj tus kheej / tsev neeg keeb kwm ntawm medullary thyroid carcinoma (MTC) los yog ntau yam endocrine neoplasia syndrome hom 2 (MEN 2).
Hypoglycemia: Kev pheej hmoo nce ntxiv thaum ua ke nrog insulin lossis sulfonylureas- txo cov koob tshuaj ntawm cov tshuaj no los ntawm 20-50% thaum pib thiab saib xyuas cov ntshav qabzib kom zoo.
Lub raum tsis zoo: Siv ceev faj rau cov neeg mob uas muaj mob nruab nrab -rau- lub raum tsis ua haujlwm hnyav (eGFR<30 mL/min/1.73m²); avoid in end-stage renal disease.
Contraindications: Hypersensitivity rau Liraglutide los yog lwm yam excipients; MTC keeb kwm/tsev neeg keeb kwm; YOG 2; mob plab hnyuv loj (piv txwv li, gastroparesis).
Kev koom tes & kev sib cuag
Peb muab tshuaj -qib Liraglutide CAS#204656-20-2 API rau cov tuam txhab ntawm ib zaug- cov tshuaj txhaj tshuaj txhua hnub, nrog cov peev txheej tsim tau yooj yim (los ntawm qib gram-theem R&D cov qauv mus rau kilogram-theem ntau xaj). Yog tias koj yog ib lub tuam txhab kws tshuaj, R & D lub koom haum, lossis tus tsim qauv xav tau cov khoom no, thov hu rau peb rau:
Cov ntaub ntawv qhia txog kev ua raws cai ntawm pharmacopoeia (USP / EP monograph lees paub, daim ntawv pov thawj ntawm kev tshuaj xyuas).
Tus nqi quotes, bulk order discounts, thiab dawb R&D qauv thov.
Kev pab txhawb nqa (piv txwv li, formulation compatibility, koob tshuaj - nce kev taw qhia, peptide stability txij nkawm).
Cov ntaub ntawv tiv tauj:
Email: sales@huarongpharma.com
Xov tooj/WhatsApp: +86 13751168070
Peb ua raws li cov hauv paus ntsiab lus ntawm "kev ua tau zoo ua ntej, ua raws li- taw qhia" thiab tos ntsoov yuav tsim kom muaj kev sib raug zoo ntev -, kev sib raug zoo nrog kev sib raug zoo nrog cov neeg koom tes thoob ntiaj teb!
Cov lus nug nquag nug (FAQs)
1. Cov kev mob tshwm sim ntawm Liraglutide yog dab tsi?
Cov kev mob tshwm sim feem ntau yoggastrointestinal ntshawv siab, nrog rau xeev siab (30-45% ntawm cov neeg mob), raws plab (15-30%), cem quav (10-20%), ntuav (5-15%), thiab tsis qab los noj mov (15-25%). Cov no feem ntau yog nyob ntawm koob tshuaj, tshwm sim hauv thawj 2-4 lub lis piam ntawm kev kho mob, thiab feem ntau daws nrog cov tshuaj maj mam nce lossis siv txuas ntxiv. Cov kev mob tshwm sim tsawg dua muaj xws li mob taub hau, qaug zog, thiab qhov chaw txhaj tshuaj me me (liab, khaus).
2. Liraglutide ua haujlwm hauv lub cev li cas?
ua haujlwm los ntawmUa raws li endogenous GLP-1(lub plab hormone tso tawm tom qab noj mov) thiab ua kom GLP-1 receptors hauv cov kabmob tseem ceeb:
Pancreas: Ua kom cov tshuaj insulin tso tawm (tsuas yog thaum cov ntshav qabzib nce siab, tsis txhob muaj cov piam thaj hauv ntshav) thiab inhibits glucagon secretion (txo cov piam thaj hauv siab).
Kab mob plab: Slows gastric emptying, ncua kev nqus cov as-ham thiab txo cov ntshav qabzib tom qab spikes.
Lub hlwb: Ua haujlwm ntawm hypothalamus kom txo qis qab los noj mov thiab ua kom satiety, txo cov zaub mov kom tsawg thiab txhawb kev poob phaus.
Ntev Ib nrab-Lub Neej: Cov kab mob fatty acid txuas nrog peptide khi rau albumin hauv cov hlab ntsha, ua rau lub raum tsis ua haujlwm qeeb thiab ua rau ib zaug - noj txhua hnub.
3. Puas muaj kev cuam tshuam tshuaj nrog Liraglutide?
Yog lawm, muaj peev xwm ua kom qeeb plab hnyuv yuav cuam tshuam rau kev nqus ntawm lwm cov tshuaj hauv qhov ncauj. Cov kev sib tham tseem ceeb muaj xws li:
Qhov ncauj Hypoglycemic Agents: Kev siv ua ke nrog insulin lossis sulfonylureas (piv txwv li, glimepiride) ua rau muaj kev pheej hmoo ntawm hypoglycemia - txo qis koob tshuaj insulin / sulfonylureas los ntawm 20-50% thaum xub thawj.
Cov tshuaj tiv thaiv qhov ncauj: Tej zaum yuav ncua kev nqus (nce siab concentration txo los ntawm ~ 20%); muab cov tshuaj tiv thaiv tsawg kawg 1 teev ua ntej txhaj tshuaj Liraglutide.
Tshuaj tua kab mob/Antifungals: Cov tshuaj uas xav tau kev nqus sai (xws li amoxicillin, fluconazole) yuav tsum tau noj 1 teev ua ntej lossis 2 teev tom qab Liraglutide kom tsis txhob nqus tau qeeb.
Beta{0}}Blockers: Tej zaum yuav npog cov tsos mob hypoglycemia (piv txwv li, tachycardia); saib xyuas cov ntshav qabzib kom ze rau hauv kev tswj hwm co-.
Glucocorticoids: Tej zaum yuav qaug zog yog qabzib- txo qis; nce kev soj ntsuam qabzib thiab kho cov koob tshuaj yog tias xav tau.
Cim npe nrov: Liraglutide cas#204656-20-2, Tuam Tshoj liraglutide cas#204656-20-2 manufacturers, lwm tus neeg
 - Fluoroquino9b7a2.png?size=118x0)